Clinical Scorecard: Evaluating Quality of Life Following Stereotactic Radiosurgery for Brain Metastases: Insights from a National Prospective Registry
At a Glance
Category
Detail
Condition
Brain metastases from primary cancers such as lung, breast, and melanoma
Key Mechanisms
Stereotactic radiosurgery (SRS) delivers precise ionizing radiation to intracranial metastatic lesions to control tumor growth and preserve neurological function
Target Population
Adult patients with brain metastases undergoing SRS treatment
Care Setting
Multi-institutional clinical centers participating in the NeuroPoint Alliance SRS Registry
Key Highlights
Brain metastases are the most common intracranial tumors in adults, with increasing incidence due to enhanced MRI screening.
SRS offers superior local tumor control and cognitive preservation compared to whole-brain radiotherapy, positively impacting quality of life.
The NeuroPoint Alliance SRS Registry prospectively collects real-world data on patient demographics, treatment, tumor characteristics, and quality of life outcomes.
Guideline-Based Recommendations
Diagnosis
Use brain MRI for screening and surveillance of brain metastases in patients with primary cancers prone to CNS spread.
Assess baseline functional status using Karnofsky Performance Status (KPS) and patient-reported EQ-5D-5L quality of life questionnaire.
Management
Consider stereotactic radiosurgery as a minimally invasive treatment option for brain metastases to achieve local tumor control and preserve cognitive function.
Tailor SRS dosimetry parameters (prescription dose, margin dose, number of fractions) based on tumor characteristics and patient factors.
Monitoring & Follow-up
Perform longitudinal assessment of quality of life using EQ-5D questionnaires at baseline, 6–12 months, and final follow-up.
Monitor for local progression defined by ≥72.8% increase in lesion volume per RANO-BM criteria and for out-of-field progression with new metastases.
Use time-to-event analyses for overall survival and intracranial progression to guide ongoing care.
Risks
Potential neurological symptoms and psychological burden associated with brain metastases.
Risk of tumor progression locally or outside the treated field despite SRS.
Consider comorbidities such as diabetes, coronary artery disease, and smoking status in treatment planning.
Patient & Prescribing Data
Patients with brain metastases from lung cancer, breast cancer, or melanoma enrolled in a national prospective registry.
SRS treatment is associated with preservation of pre-treatment functional capacity and quality of life, with data supporting its use over whole-brain radiotherapy for cognitive outcomes.
Clinical Best Practices
Incorporate patient-reported quality of life measures (EQ-5D) into routine clinical assessment pre- and post-SRS.
Use volumetric and lesion count metrics to stratify patients and guide SRS treatment planning.
Employ multi-institutional registry data to inform quality improvement and evidence-based care decisions.
Impute missing baseline data using validated statistical methods to maintain analytic robustness.
